Science

10/28/26

Tyra’s Dabogratinib and the FGFR3 Switch That Makes Cells Both Stop and Go

Biotech

Science

Finance

10/08/26

Weight Loss? We’re Betting on a Future Where People Don’t Gain Weight in the First Place

Biotech

Science

Culture

Finance

07/17/26

Parabilis’ Zolucatetide: The Societal Value of a Drug That Wasn’t Supposed to Exist

Biotech

Science

Finance

07/14/26

Fermenting Change: Where Biology Wins and Biomanufacturing Scales Next

Planetary

Science

Finance

05/01/26

The infectious positivity of Mario Barro

Biotech

Science

Culture

04/02/26

The ocean’s blind spot: Why better forecasts start beneath the surface

Finance

Science

Planetary

03/31/26

Planetary Health March Madness: Efficient Compute Takes the Crown

Finance

Policy

Science

Planetary

12/19/25

What you were reading — Rapport’s top stories of 2025

Biotech

Culture

Finance

Policy

Science

09/22/25

The CDC once rescued my faith in science — who will rescue us now?

Biotech

Culture

Policy

Science

09/17/25

Proposals for Modernizing IND Processes, Clinical Trial Development, and Good Clinical Practice Standards

Biotech

Policy

Science

08/19/25

Capstan: The Story of the Open Minds Behind the Acquisition of an In Vivo CAR‑T Pioneer

Culture

Finance

Science

06/26/25

A Cautious FDA Also Threw Out the Baby: In restricting the label for COVID-19 vaccines, the FDA is being too conservative

Biotech

Policy

Science

05/27/25

Agriculture: Hiding in Plain Sight

Culture

Science

Planetary

05/14/25

Writing the future of genetic medicines, with Stylus

Biotech

Finance

Science

03/06/25

The Great Salt Lake: getting more minerals with less water

Policy

Science

Planetary

02/15/25

A Vaccine for your Mind

Biotech

Culture

Science

12/20/24

What you were reading — Rapport’s top stories of 2024

Biotech

Culture

Finance

Policy

Science

Planetary

12/18/24

ESPN always shows the struggle; this time, it’s mine

Biotech

Culture

Science

11/13/24

Managing pain without opioids is on the horizon – if we decide it’s worth it

Biotech

Policy

Science

10/28/24

Raven-built Aliada shuttles its potential best-in-class Alzheimer’s treatment to AbbVie

Biotech

Finance

Science